Bibliographic Details
| Title: |
Oncobox Platform of RNA Sequencing and Bioinformatic Analysis for Personalized Prescription of Targeted Drugs: Results of Prospective Clinical Trial NCT03724097. |
| Authors: |
Sorokin, Maxim, Garazha, Andrew, Suntsova, Maria, Tkachev, Victor, Poddubskaya, Elena, Gaifullin, Nurshat, Sushinskaya, Tatiana, Lantsov, Dmitriy, Borisov, Vasiliy, Naskhletashvili, David, llyin, Kirill, Seryakov, Alexander, Glusker, Alex, Moisseev, Alexey, Buzdin, Anton |
| Source: |
Journal of Immunotherapy & Precision Oncology; Aug2024, Vol. 7 Issue 3, p218-219, 2p |
| Subject Terms: |
RNA sequencing, DRUGS, DRUG therapy, GENE expression, PALLIATIVE treatment |
| Abstract: |
Introduction: Interrogating gene expression in tumor can identify up- and downregulated molecular targets of cancer drugs. Here we report the results of prospective clinical investigation NCT03724097 of using RNA sequencing analysis for personalized cancer therapy. Methods: Transcriptomic profiles were analyzed using computational algorithm Oncobox that identifies altered expression of drug target genes and molecular pathways and builds a personalized rating of targeted therapeutics. Oncobox reports were provided to oncologists, and treatment outcomes were assessed. Results: Totally, 239 adult solid cancer patients were enrolled: 135 received cancer drug therapy, others received palliative treatment or radiotherapy, or died before therapy started. Oncobox recommended drugs were prescribed in 59% of the cases receiving therapy. Otherwise, patients received non-targeted therapy or targeted therapy predicted as inefficient by Oncobox (controls). Patients in the Oncobox group were significantly pre-treated compared to controls (mean number of previous lines therapy 2 vs 1.2, respectively), but we observed a longer progression-free survival (PFS) trend in the Oncobox group. Furthermore, post-hoc analysis revealed that time between biopsy collection and tumor molecular profiling significantly impacts Oncobox predictive capacity. Excluding patient cases with biopsy obtained more than 7 months before RNA sequencing led to a statistically significant difference in PFS between Oncobox and control groups with hazard ratio of 0.45 (95% CI: 0.23-0.9,p-value = 0.023). Conclusion: These results suggest that transcriptomic profiling provides clinically relevant therapeutic match and can improve disease control rate in recurrent and/or metastatic solid cancers. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Immunotherapy & Precision Oncology is the property of Innovations Journals and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
